A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients

NCT04200040 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL: OrienX010 injection
DRUG: Dacarbazine (DTIC)

Sponsor

OrienGene Biotechnology Ltd.